Volume 15 Supplement 4
Edited by Anne De Groot, Yongqun He and Phoebe De Groot
Publication of this supplement has not been supported by sponsorship. Information about the source of funding for publication charges can be found in the individual articles. Articles have undergone the journal's standard review process for supplements. Anne De Groot declares that she is the founder and majority shareholder at EpiVax Inc., a privately owned vaccine design company located in Providence, Rhode Island, USA which developed and owns the right to the iVAX platform. The Supplement Editors declare that there is a potential conflict of interest related to Dr De Groot's relationship with EpiVax and attest that the work contained in this supplement is free of any bias that might be associated with the commerical goals of the company. The other Supplement Editors declare that they have no competing interests.
The 3rd ISV Pre-conference Computational Vaccinology Workshop (ICoVax 2013). Go to conference site.
Barcelona, Spain26 October 2013
Following last year's computational vaccinology workshop in Shanghai, China, the third ISV Pre-conference Computational Vaccinology Workshop (ICoVax 2013) was held in Barcelona, Spain. ICoVax 2013 provided an ...
Immune recognition of foreign proteins by T cells hinges on the formation of a ternary complex sandwiching a constituent peptide of the protein between a major histocompatibility complex (MHC) molecule and a T...
Since the first DNA vaccine studies were done in the 1990s, thousands more studies have followed. Here we report the development and analysis of DNAVaxDB (
Western drugs have achieved great successes in CVDs treatment. However, they may lead to some side effects and drug resistance. On the other hand, more and more studies found that Traditional Chinese herbs hav...
Citation Impact
3.328 - 2-year Impact Factor (2021)
4.341 - 5-year Impact Factor (2021)
1.105 - SNIP (Source Normalized Impact per Paper)
1.246 - SJR (SCImago Journal Rank)
Speed
15 days to first decision for all manuscripts (Median)
56 days to first decision for reviewed manuscripts only (Median)
Usage
6,337,109 Downloads (2021)
8,344 Altmetric mentions (2021)